Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk-Reference-Cited by-同舟云学术

Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk

Published:2019-01 Issue:1 Volume:12 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ Cardiovasc Qual Outcomes

Author:

Baber Usman¹,Leisman Daniel E.¹,Cohen David J.²,Gibson C. Michael³,Henry Timothy D.⁴,Dangas George¹,Moliterno David⁵,Kini Annapoorna¹,Krucoff Mitchell⁶,Colombo Antonio⁷,Chieffo Alaide⁷,Sartori Samantha¹,Witzenbichler Bernhard⁸,Steg Philippe Gabriel⁹,Pocock Stuart J.¹⁰,Mehran Roxana¹

Affiliation:

1. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (U.B., D.E.L., G.D., A.K., S.S., R.M.).

2. Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City (D.J.C.).

3. Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.).

4. The Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (T.D.H.).

5. Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington KY (D.M.).

6. Duke University Medical Center, Duke Clinical Research Institute, Durham, NC (M.K.).

7. Cardio-Thoracic Department, San Raffaele Scientific Institute, Milan, Italy (A. Colombo, A. Chieffo).

8. Helios Amper-Klinikum, Dachau, Germany (B.W.).

9. Université Paris-Diderot, Sorbonne Paris-Cité, France (P.G.S.).

10. London School of Hygiene and Tropical Medicine, United Kingdom (S.J.P.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Rate of Percutaneous Coronary Intervention for the Management of Acute Coronary Syndromes and Stable Coronary Artery Disease in the United States (2007 to 2011)

2. Hospitalization Costs for Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention in the United States Are Substantially Higher Than Medicare Payments

3. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

4. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

5. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.;Bittl JA;Circulation,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”;American Journal of Cardiovascular Drugs;2024-01-25

2. Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention;Mayo Clinic Proceedings;2023-07

3. Balancing the Risks of Recurrent Ischaemic and Bleeding Events in a Stable Post ACS Population;Heart, Lung and Circulation;2022-10

4. The virtual patient – Estimating the health utility of aspirin in simulated populations;IJC Heart & Vasculature;2021-10

5. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome;European Cardiology Review;2021-06-18